The new vaccine provides much greater protection than an older, single-shot vaccine from a disease that affects one in three adults and can cause debilitating nerve pain that can last months, even years.
A national shortage of a new vaccine to protect against the painful rash known as shingles is worsening, say pharmacists and consumers, even as the manufacturer announced plans last week for more consistent deliveries.
Demand for the two-dose Shingrix vaccine has skyrocketed since it became broadly available in the United States in the spring. The new vaccine provides much greater protection than an older, single-shot vaccine from a disease that affects one in three adults and can cause debilitating nerve pain that can last months, even years.
Demand is surging because federal health officials last year recommended it for healthy adults at age 50, a decade earlier than previous recommendations. Federal health officials also urged it for people who have had shingles and those who received the old vaccine, or have had or are unsure if they have had chickenpox. Those recommendations took British drugmaker GlaxoSmithKline (GSK) by surprise, leaving it scrambling to keep up with demand, say company representatives.
Company officials estimate 115 million people in the United States, who are 50 and older, are eligible for the vaccine. Shingles, a painful condition that causes blisters, occurs when the chickenpox virus resurfaces decades later. There are an estimated 1 million cases of shingles each year in the United States; the risk of the disease increases as people age.
Most Read Nation & World Stories
- Mueller concludes Russia-Trump probe with no new indictments WATCH
- Jimmy Kimmel reacts to Spokane backlash proving Gonzaga's existence, then picks Zags to win NCAA tournament
- Witness describes death plunge of two Yosemite climbers
- Flight attendant detained by immigration on return to US
- 'If you took it all in in one day, it would kill you': What Mueller's investigation has already revealed
“All I want for Christmas is for my pharmacy to get some Shingrix,” one woman tweeted last week.
Consumers have been searching for pharmacies with Shingrix doses on neighborhood listservs, in postings on social media and in visits to pharmacy after pharmacy. A Pennsylvania man wrote on Facebook a week ago that his wife was told by her local supermarket pharmacy that the waiting list was about 12 months. A CVS pharmacist in Gaithersburg, Maryland, and a Walgreens pharmacist in downtown Washington, D.C., said they hadn’t received any shipments since August.
“It’s worse now,” said a pharmacist at Walgreens, who declined to give her name. The pharmacy is not keeping a waiting list because “there’s no promise of when it’s going to come out again.”
“As soon as they get it in, it’s going out pretty quick,” said Michael Rothholz, chief strategy officer for the American Pharmacists Association.
Pharmacies began offering the vaccine broadly in mid-March. By May, the Centers for Disease Control and Prevention (CDC) was reporting shortages. Since the spring, drugstore chain CVS has had difficulty keeping an ample supply across the chain’s 9,800 stores and more than 1,100 clinics because of limited supply from the manufacturer, said spokeswoman Amy Lanctot.
Shipments arrive about every three weeks, she said. The supply “did get a little better in the fall,” she said. But since then, it has gotten worse, she said. “It’s just not being made in the amounts that are needed.”
Complicating the situation is the recommendation for consumers to get their second dose within two to six months of the first. Many consumers are struggling to find their second dose. Pharmacies are supposed to give priority to those patients. Some pharmacies are requiring consumers to get their second dose at the same place they got their first shot. Others will give the second shot if consumers show proof they have gotten the first one, regardless of where.
Consumers are confused.
A woman who got her first shot in Del Ray Beach, Florida, in August was searching for her second in Brooklyn, New York, last week. “None to be found anywhere,” she tweeted.
The CDC says patients who wait longer than six months don’t have to start over. But they should get the second dose as soon as possible because the maximum immunity — more than 90 percent — is based on two doses. Protection stays above 85 percent for at least the first four years after vaccination, the CDC says. GlaxoSmithKline did not study how much immunity is provided by one dose.
Shingrix is covered by most insurance drug plans, including Medicare Part D. The vaccine’s wholesale price is $140 per dose, but patients without insurance coverage will be paying more than that, sometimes as high as $200 or more for each shot after administration fees are added.
Sean Clements, a spokesman for GSK, said the manufacturer has increased and accelerated supply of Shingrix in the United States, shipping “large volumes” every two to three weeks. Starting in December, Clements said the company will move to a twice-monthly shipping schedule. He declined to provide specifics. A GSK representative from the company’s customer-service line said 300,000 doses were shipped in November, and an additional 160,000 doses were shipped Dec. 3.
The company makes Shingrix at a facility in Rixenstart, Belgium, which is operating at maximum capacity, the representative said. It takes six to nine months to produce the vaccine.
As of Oct. 1, almost 7 million doses of the vaccine had been administered worldwide since the vaccine’s launch in late November 2017, with most of it going to the United States.